Profile data is unavailable for this security.
About the company
Eurofins Scientific SE is a Luxembourg-based company engaged in the business support services industry. The Company joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. It operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain.
- Revenue in EUR (TTM)6.51bn
- Net income in EUR516.50m
- Incorporated2012
- Employees61.80k
- LocationEurofins Scientific SE23 val FleuriLUXEMBOURG 1526LuxembourgLUX
- Websitehttps://www.eurofins.com/
More ▼
Mergers & acquisitions
Acquired company | ERF:PAR since announced | Transaction value |
---|---|---|
Ascend Clinical LLC | -3.90% | -- |
SGS SA-North American Crop Science Operations | -0.59% | -- |
Quasfar SA | 9.08% | -- |
Data delayed at least 15 minutes, as of May 24 2024 09:37 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Grifols SA | 6.59bn | 59.31m | 5.60bn | 23.74k | 101.52 | 1.07 | 8.99 | 0.8493 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
BACHEM HOLDING AG | 583.84m | 113.12m | 6.57bn | 2.01k | 57.80 | 4.92 | 41.38 | 11.26 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Croda International Plc | 1.99bn | 200.80m | 7.53bn | 5.85k | 37.56 | 2.73 | 21.50 | 3.79 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
Swedish Orphan Biovitrum AB (publ) | 1.99bn | 184.42m | 8.55bn | 1.75k | 45.27 | 2.65 | 17.87 | 4.29 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Qiagen NV | 1.82bn | 315.64m | 8.86bn | 5.97k | 28.47 | 2.52 | 17.52 | 4.87 | 1.41 | 1.41 | 8.12 | 15.91 | 0.3169 | 1.93 | 5.38 | 304,598.50 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Recordati Industria Chmc Frmctc SpA | 2.14bn | 388.86m | 10.15bn | 4.46k | 27.05 | 5.51 | 18.68 | 4.74 | 1.79 | 1.79 | 9.92 | 8.81 | 0.5177 | 1.67 | 4.53 | 480,087.10 | 9.41 | 11.67 | 12.13 | 15.02 | 67.82 | 70.43 | 18.18 | 21.45 | 0.9518 | 7.55 | 0.4883 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
Ipsen SA | 3.31bn | 617.10m | 10.36bn | 5.33k | 16.72 | 2.67 | 10.82 | 3.13 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
Eurofins Scientific SE | 6.51bn | 516.50m | 11.14bn | 61.80k | 22.11 | 2.18 | 9.83 | 1.71 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
BioMerieux SA | 3.67bn | 357.60m | 11.21bn | 14.65k | 31.47 | 2.98 | 18.19 | 3.05 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
Sandoz Group AG | -101.13bn | -101.13bn | 14.07bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Eurofins Scientific SE's reporting currency: Euro EUR
Holder | Shares | % Held |
---|---|---|
Harris Associates LPas of 31 Mar 2024 | 5.35m | 2.77% |
The Vanguard Group, Inc.as of 09 May 2024 | 4.62m | 2.39% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 4.22m | 2.19% |
Mawer Investment Management Ltd.as of 31 Dec 2023 | 4.13m | 2.14% |
Capital International Ltd.as of 09 May 2024 | 3.31m | 1.72% |
T. Rowe Price Associates, Inc. (Investment Management)as of 10 May 2024 | 3.30m | 1.71% |
RBC Global Asset Management (UK) Ltd.as of 29 Mar 2024 | 2.85m | 1.48% |
Impax Asset Management Ltd.as of 30 Apr 2024 | 2.77m | 1.44% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.73m | 1.42% |
Ruane, Cunniff & Goldfarb LPas of 29 Dec 2023 | 2.49m | 1.29% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.